Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.

Hodgkin lymphoma and other malignancies that express the CD30 protein have been the scourge of oncologists for decades. For patients whose cancer returns or is treatment-refractory, choices are ...

Digital patient profiles and real-world data enhance oncology trial design, patient recruitment, and reduce trial failure risks. Phesi's platform aligns trial designs with real-world data, minimizing ...